This randomised, open-label, phase I/II study evaluated the efficacy and safety of nintedanib, an oral, triple angiokinase inhibitor, combined with chemotherapy, relative to bevacizumab plus chemotherapy as first-line therapy in patients with metastatic colorectal cancer (mCRC). , every 2 weeks) or bevacizumab (5 mg/kg every 2 weeks) plus mFOLFOX6. During phase I, patients underwent a 3 + 3 dose-escalation schema to determine the maximum tolerated dose (MTD) of nintedanib in combination with mFOLFOX6. The primary end point was progression-free survival (PFS) rate at 9 months. Objective response (OR) was a secondary end point.
introduction Anti-angiogenic therapy with bevacizumab, a humanised antivascular endothelial growth factor (VEGF) monoclonal antibody, is now an established first-line treatment option for patients with advanced unresectable colorectal cancer (CRC). This strategy was validated by the observation that adding bevacizumab to standard chemotherapy significantly improved overall survival (OS) and progression-free survival (PFS) versus chemotherapy alone [1] . However, contemporary chemotherapy regimens (such as FOLFOX or FOLFIRI) plus bevacizumab confer OS of only ∼20-30 months and PFS of ∼10 months [2] . Therefore, there is a clear need for better treatment strategies in patients with advanced CRC.
Recent phase III trials of anti-angiogenic tyrosine kinase inhibitors (TKIs) plus standard chemotherapy have failed to demonstrate a survival advantage versus chemotherapy alone in patients with advanced CRC [3] . One explanation for these failures is that TKI-associated adverse events (AEs) may result in reduced intensity of treatment dosing [3] . Alternatively, tumours may 'escape' anti-angiogenic inhibition by up-regulating compensatory pro-angiogenic pathways. Accumulating evidence indicates that platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) signalling pathways are activated in response to VEGF inhibition [4] [5] [6] .
Nintedanib (Vargatef®) is an oral, triple angiokinase inhibitor, which targets VEGFR 1-3, PDGFR-α/-β and FGFR1-3, in addition to Flt3 [7] , and has been approved in the European Union (EU) for the treatment of NSCLC patients with adenocarcinoma tumour histology after first-line chemotherapy and by the EU and the US Food and Drug Administration for patients with idiopathic pulmonary fibrosis (Ofev®) [8] . Single-agent nintedanib demonstrated manageable tolerability and encouraging clinical activity in a phase I study that included 30 patients with advanced/ refractory CRC [9] . This phase I/II study (NCT00904839) was conducted to evaluate the efficacy and safety of nintedanib plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 as first-line therapy in patients with unresectable mCRC.
patients and methods
Eligible patients were aged ≥18 years with mCRC histologically proven as adenocarcinoma, which was not amenable to potentially curative treatment, and with ≥1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST). Prior systemic therapy for metastatic disease was not permitted. Prior surgery or systemic therapy for local disease was permitted with the exception of no previous oxaliplatin-based chemotherapy unless disease-free survival after the end of chemotherapy was ≥12 months and no previous adjuvant therapy with fluoropyrimidines unless disease-free survival after the end of chemotherapy was >6 months. Additional patient eligibility criteria are listed in the supplementary Table S1 , available at Annals of Oncology online. The trial was undertaken in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice. The study protocol was approved by the institutional review board of each participating centre. All patients provided written informed consent before participating.
study design and treatments
This was an open-label, randomised, parallel group, phase I/II, study conducted at 27 centres in five Western European countries. The study was exploratory and designed to provide insight into the efficacy and safety of nintedanib plus mFOLFOX6 in patients with CRC, with the potential for a subsequent larger-scale trial. A bevacizumab-containing treatment arm was included for clinical context; however, the study was not powered to allow a formal statistical comparison between the treatment arms.
Given that the clinical profile of bevacizumab plus mFOLFOX6 is well established, patients were randomised 2:1 to receive nintedanib (150 Figure S1 ) and definition of DLT (supplementary Table S2 ) are provided in the supplementary material, available at Annals of Oncology online.
phase II part. The efficacy, safety and pharmacokinetics (PK) of study treatment were assessed in the phase II part of the trial using the nintedanib maximum tolerated dose (MTD) from phase I. Patients included in the phase I part of the study were also included in phase II. The phase II part comprised the period from the end of phase I until the last patient had died, progressed, received other anticancer therapy or been lost to follow-up. Nintedanib dose reductions were allowed in the event of drug-related AEs following a protocol-defined dose reduction scheme based on AE severity and type. Reducing the bevacizumab dose due to AEs was not recommended; if indicated, bevacizumab was either permanently discontinued or temporarily suspended.
assessments
The objective of the phase I part of the study was to determine the MTD of the treatment regimen in the nintedanib arm. The MTD was defined as the highest nintedanib dose where no more than one-third of patients experienced a DLT during the first two treatment cycles. Safety and efficacy were also assessed and blood samples were collected to determine the PK of nintedanib and its metabolites, as well as oxaliplatin, and 5-FU (supplementary Table S3 , available at Annals of Oncology online). Plasma concentrations of nintedanib (and metabolites) were determined by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay. The primary end point of the phase II part was 9-month PFS rate, defined as the proportion of patients without objective disease progression and alive 9 months after randomisation. This primary end point was chosen on the basis that this time period corresponded approximately to the median PFS for the combined bevacizumab plus mFOLFOX6 regimen [10] . A primary end point of the 9-month PFS rate also offers the practical advantage over a PFS event-driven statistical method of allowing early analysis at a fixed time point, 9 months after the last patient is recruited into the study. Efficacy and safety data from this early analysis have been presented previously in abstract form [11] and are consistent with data presented here. Secondary end points included OS, PFS, objective response (OR), resection rate (colon or metastases) and tumour shrinkage. Tumour response was based on the response of target, non-target and new lesions according to RECIST, version 1.0, and clinical assessment. Safety was assessed by incidence and intensity of AEs graded according to Common Terminology Criteria for Adverse Events (CTCAE; version 3.0). Other safety assessments included various laboratory parameters, vital signs, electrocardiograms and physical examination. Blood samples for PK analysis of nintedanib and its metabolites were taken at various time points from all nintedanib-treated patients (supplementary Table S3 , available at Annals of Oncology online).
statistical analysis
Enrolment was planned for 12-18 patients into the phase I part of the study and 120 patients in the phase II part. Details of the sample size calculation are provided in supplementary Table S4, available original articles Annals of Oncology received at least one dose of study drug). All analyses were descriptive and exploratory in nature. No formal statistical testing was planned and statistical analyses were carried out only to provide a statistical framework from which to view the results and plan further studies. For the primary efficacy end point, asymptotic 95% confidence interval (CI) using Peto's variance estimate in each group and difference between the groups were calculated. OS was also evaluated using the Kaplan-Meier (KM) method. The main analysis (described here) was planned to take place once follow-up had concluded (a minimum of 12 months after the last patient had entered the trial).
results patient characteristics
Between June 2009 and May 2010, 136 patients were enrolled, 128 were randomised and 126 received treatment (supplementary Figure S2 , available at Annals of Oncology online). Patient demographics and baseline characteristics were well balanced between the treatment groups ( Table 1) .
MTD determination
In total, 12 patients were included in the MTD set: three received 150 mg b. Figure 1A ]. For nintedanib, the primary end point was consistent across patient subgroups while the effect of bevacizumab was more variable (supplementary Figure S3 , available at Annals of Oncology online). Median PFS was 10.5 months (95% CI 9.4-12.4) in the nintedanib group and 15.4 months (95% CI 9.6-18.9) in the bevacizumab group. The proportion of censored patients who discontinued the study without progressive disease was higher in the bevacizumab versus nintedanib treatment arm [n = 16 (39%) versus n = 23 (27%); supplementary Figure S2 , available at Annals of Oncology online]. Therefore, a post hoc sensitivity analysis of PFS was undertaken in which all censored patients in both treatment arms were assumed to have had an event at the date of censoring. In this analysis, median PFS was 8.5 months (95% CI 7.1-9.9) in the nintedanib group and 9.3 months (95% CI 6.5-10.6) in the bevacizumab group ( Figure 1B) . Secondary efficacy end points in the nintedanib and bevacizumab groups are summarised in Table 2 . The incidence of a confirmed OR was 63.5% versus 56.1% in the nintedanib versus bevacizumab groups, respectively; while the median duration of confirmed OR was 8.2 versus 12.4 months. KM estimates for median OS could not be calculated because of an insufficient number of deaths (supplementary Figure S4 , available at Annals of Oncology online). The frequencies of resection were 15.3% in the nintedanib group and 22.0% in the bevacizumab group [of which 46.2% and 77.8%, respectively, were complete resections (R0); Table 2 ]. The minimum percentage increase changes in the sum of longest diameters of target lesions were similar for both groups (supplementary Figure S5 , available at Annals of Oncology online).
safety
Mean treatment exposure was similar between the groups (nintedanib: 236.1 days; bevacizumab: 225.8 days). The most frequently reported AEs (incidence >40% in either group) were diarrhoea, nausea, asthenia, neutropenia, vomiting, decreased appetite and constipation (Table 3) . Gastrointestinal and haematological events occurred more frequently with nintedanib versus bevacizumab. The incidence of patients with at least one AE considered related to study medication was 98.8% in the nintedanib group and 97.6% in the bevacizumab group. The most common grade ≥3 AEs were neutropenia, diarrhoea, neurotoxicity, paraesthesia and asthenia. The overall incidence of serious AEs (SAEs) was 37.6% for the nintedanib group and 53.7% for the bevacizumab group. The most common SAEs (nintedanib versus bevacizumab) were pyrexia (5.9% versus 0%), pulmonary embolism (4.7% versus 0%), diarrhoea (3.5% versus 7.3%), intestinal obstruction (3.5% versus 7.3%) and abdominal pain (2.4% versus 4.9%). Incidences of AEs leading to permanent discontinuation of randomised treatment (with or without discontinuation of mFOLFOX6) were 27.1% in the nintedanib group and 31.7% in the bevacizumab group. Among AEs of special interest associated with VEGF inhibitor therapy (Table 3) , the incidence of patients with bleeding was 25.9% in the nintedanib group but higher at 41.5% in the bevacizumab group, primarily due to an increased incidence of epistaxis with bevacizumab. Analysis of other AEs of special interest did not reveal any excess clinical risk in the nintedanib group (see Table 3 ).
Five patients died during the on-treatment period (two nintedanib patients; three bevacizumab patients). AEs leading to death were sepsis, intestinal perforation, hepatic failure and renal failure (all in one nintedanib patient); aggravated condition (one nintedanib patient); intestinal perforation, intestinal obstruction and general deterioration of physical health (reported for one bevacizumab patient each).
AEs of increased liver enzymes were more frequent in the nintedanib group versus the bevacizumab group for ALT (5.9% versus 2.4%), AST (4.7% versus 2.4%) and GGT (5.9% versus 4.9%), but were reversible during treatment. Hyperbilirubinaemia occurred in one patient in the nintedanib group and in no patients in the bevacizumab group. There were no clinically noteworthy changes in vital signs. Table S6 , available at Annals of Oncology online). Concomitant administration of mFOLFOX6 did not change the PKs of nintedanib and its metabolites BIBF 1202 and BIBF 1202-glucuronide (supplementary Table S7 , available at Annals of Oncology online). During phase II, trough plasma concentrations of nintedanib and its metabolites remained stable over the treatment period.
discussion
This phase I/II study determined that the MTD of nintedanib in combination with mFOLFOX6 was 200 mg b.i.d. and demonstrated clinical efficacy and an acceptable safety profile for this combination in patients with mCRC.
There was no significant difference in the primary end point of PFS rate at 9 months between the arms, although the median PFS favoured bevacizumab over nintedanib. However, all analyses undertaken in this trial were descriptive and exploratory by nature and the study was not powered to determine a statistical difference between treatments. The median PFS of 15.4 months with bevacizumab plus mFOLFOX6 in this study is high in comparison with previous reports of 10.3 months for this regimen in a large-scale (N = 1422) phase III study [12] and values of 11.0, 12.6 and 15.9 months in smaller studies [13] [14] [15] . The high median PFS with bevacizumab in this study may be due to the higher proportion of patients who discontinued the study without progressive disease and were censored from the analysis, as well as the relatively high number of patients who underwent tumour resection. Indeed, post hoc sensitivity analyses indicated that PFS was impacted by an imbalance in censoring between treatment arms for patients who discontinued ( possibly due to the unblinded study design). Consequently, the robustness of conclusions relating to PFS from this study is limited. Notwithstanding the obvious pitfalls of inter-trial comparisons, the median PFS observed with nintedanib plus mFOLFOX6 in this study of an unselected mCRC patient population are comparable with data for EGFR inhibitors cetuximab and panitumumab plus FOLFOX in RAS wild-type mCRC patients [16, 17] . The AE profile of nintedanib plus mFOLFOX6 was consistent with previous findings for nintedanib. Fewer patients discontinued treatment due to an AE or SAE with nintedanib versus bevacizumab. The nintedanib group reported fewer incidences of bleeding, hypertension, rash and thromboembolic events versus the bevacizumab group, although the proportion of patients with an SAE of pulmonary embolism was higher with nintedanib versus bevacizumab. Additionally, there were low incidences of cardiac failure and gastrointestinal perforation reported with nintedanib. The incidence of hand-foot syndrome was lower in the nintedanib versus the bevacizumab arm. Evidence indicates that bevacizumab augments the risk of hand-foot syndrome associated with 5-FU-based regimens, although the mechanistic basis of this effect is unclear [10, 18] . Markedly low rates of hand-foot syndrome have also been observed with nintedanib monotherapy versus sunitinib monotherapy in patients with advanced renal cell carcinoma [19] , and in large-scale phase III studies of nintedanib plus docetaxel [20] or plus pemetrexed [21] in patients with non-small-cell lung cancer. PK parameters for nintedanib and mFOLFOX6 components were essentially unaffected by co-administration.
Thus far, results with anti-angiogenic TKIs have been disappointing in mCRC [3] . Possible explanations include excessive toxicity, other pharmacodynamic interactions between TKIs and 
